Skip to main content
CGEM
NASDAQ Life Sciences

Cullinan's CLN-978 Shows Favorable Safety Profile in Phase 1 Trial

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$13.58
Mkt Cap
$830.298M
52W Low
$5.68
52W High
$16.74
52W Position info
139% above low
Off High info
19% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

CGEM has more than doubled off its 52-week low of $5.68.

Summary

Cullinan Therapeutics announced its drug candidate CLN-978 demonstrated a favorable safety profile in its Phase 1 trial, specifically with single target doses up to 30 µg and an initial multi-dose regimen. This provides more specific details following the company's announcement on May 18th of positive initial Phase 1 clinical data for CLN-978. A favorable safety profile is a critical milestone for a drug in early-stage clinical development, helping to de-risk the program and support the company's overall pipeline valuation. This positive update is important for investor confidence, especially after the Q1 2026 report indicated a reduced cash runway.

At the time of this announcement, CGEM was trading at $13.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $830.3M. The 52-week trading range was $5.68 to $16.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

CGEM - Latest Insights

CGEM
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.35
Real-time Price: $10.71 info
Change: -$2.64 (-20%) info
Market Cap: $695.031M info
CGEM
Oct 01, 2026, 7:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.55
Real-time Price: $10.71 info
Change: -$3.84 (-26%) info
Market Cap: $695.031M info
CGEM
Sep 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $16.88
Real-time Price: $10.71 info
Change: -$6.17 (-37%) info
Market Cap: $695.031M info
CGEM
Sep 14, 2026, 7:29 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.60
Real-time Price: $10.71 info
Change: -$9.89 (-48%) info
Market Cap: $695.031M info
CGEM
Sep 13, 2026, 7:15 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $21.11
Real-time Price: $10.71 info
Change: -$10.40 (-49%) info
Market Cap: $695.031M info